Peptide Comparison
Immunoxel (Dzherelo)vsThymosin Beta-4
Ukrainian botanical immunomodulator that supercharges tuberculosis treatment and restores immune function in HIV patients
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Immunoxel (Dzherelo)
25–50 drops
Thymosin Beta-4
2–5 mg
Frequency
Immunoxel (Dzherelo)
Multiple times daily
Thymosin Beta-4
Twice weekly
Administration
Immunoxel (Dzherelo)
Oral (liquid drops)
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Immunoxel (Dzherelo)
8-12 weeks
Thymosin Beta-4
8-12 weeks
Onset Speed
Immunoxel (Dzherelo)
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Immunoxel (Dzherelo)
Moderate human trials (Phase 1-2)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
TB Treatment Enhancement
Immune Restoration
Infection Prevention
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Immunoxel (Dzherelo)
Molecular Formula
N/A — multi-component herbal phytoconcentrate
Molecular Weight
N/A — complex botanical mixture of multiple plant compounds
Half-Life
Not precisely characterized; immunomodulatory effects develop over days to weeks of consistent dosing
Bioavailability
Good oral and sublingual bioavailability; sublingual lozenges shown equivalent to twice-daily oral liquid
CAS Number
Proprietary combination
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Protocols
Dosing
tiers
Immunoxel (Dzherelo)
Thymosin Beta-4
Applications
Best
suited for
Immunoxel (Dzherelo)
Tuberculosis Adjunct Treatment
Immunoxel's strongest evidence is as an add-on to standard TB drugs. A meta-analysis of 6 clinical trials found patients receiving Immunoxel were 3.19 times more likely to become sputum-negative compared to TB drugs alone. In one study, 84.1% of patients converted within 1 month versus only 19% on placebo.
HIV/TB Coinfection Immune Support
For patients battling both HIV and TB simultaneously, Immunoxel offers remarkable immune benefits. Clinical trials showed CD4+ T-cell counts increased by 71.2% in just 2 months, viral load decreased significantly, and opportunistic infections dropped from 12 episodes to just 3 compared to standard therapy alone.
Drug-Resistant Tuberculosis Support
Immunoxel has been studied in multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) patients where standard treatments often struggle. Its immune-boosting effects help the body fight TB even when the bacteria resist front-line drugs.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Immunoxel (Dzherelo)
Common
- Well-tolerated in most patients
- Mild gastrointestinal discomfort
Uncommon
- Temporary taste changes
- Mild allergic skin reactions
- Mild headache
Serious
- Potential herb-drug interactions
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Immunoxel (Dzherelo)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Immunoxel has demonstrated a favorable safety profile across multiple clinical trials involving hundreds of patients with TB and TB/HIV coinfection. No serious adverse events have been reported in published studies. It is approved by Ukraine's Ministry of Health and has been used clinically since the late 1980s. Side effects are generally mild and gastrointestinal in nature.
Contraindications
- xKnown hypersensitivity to any of the plant ingredients in the formulation
- xPregnancy and breastfeeding (insufficient safety data)
- xSevere liver disease (contains alcohol-based extract)
- xUse as sole therapy for TB or HIV (must be combined with standard treatment)
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Immunoxel (Dzherelo) if...
- Adjunct immunotherapy alongside tuberculosis treatment
- Immune restoration in HIV/TB coinfected patients
- Reducing opportunistic infection rates
- Supporting overall immune function during infectious disease treatment
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation